Sign in

Jeremy Perlman

Senior Research Associate and Equity Analyst at Maxim Group

Jeremy Perlman is a Senior Research Associate and Equity Analyst at Maxim Group LLC, specializing in coverage of emerging-growth and under-covered small- to mid-cap companies across sectors such as healthcare, technology, and retail. He provides fundamental research and investment insights on companies including Rockwell Medical and Veru, contributing to Maxim Group’s niche focus on attractive, inefficient markets and demonstrating a consistent track record of reliable recommendations for institutional investors, with his calls reflected in quarterly performance reviews and industry platforms. Perlman began his career after graduating from Queens College and has held analytical positions at Maxim Group since joining the firm, establishing a solid network of professional relationships through equity research engagements and earning recognition for his detailed industry analysis. He maintains active FINRA registration (CRD#: 5725073) and operates with securities licenses as part of his professional credentials.

Jeremy Perlman's questions to ROCKWELL MEDICAL (RMTI) leadership

Jeremy Perlman's questions to ROCKWELL MEDICAL (RMTI) leadership • Q2 2025

Question

Inquired about the stability of gross margins despite a revenue decline, the mitigation of customer concentration risk, and whether the company has capitalized on a competitor's recent product recall.

Answer

Gross margins were maintained by right-sizing the organization, investing in more efficient equipment, and because the former largest customer did not contribute significantly to margins. Customer concentration risk has been greatly reduced, with the former largest customer now representing only 10% of revenue, down from 45%. The company confirmed it is working to supplement supply for customers affected by a competitor's significant product recall, which had serious health consequences for patients.

Ask Fintool Equity Research AI